(KROS) Keros Therapeutics - Overview
Stock: KER-050, KER-012, KER-065, Elritercept
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 58.3% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.18 |
| Alpha | 50.91 |
| Character TTM | |
|---|---|
| Beta | 0.174 |
| Beta Downside | -0.578 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.45% |
| CAGR/Max DD | -0.36 |
Description: KROS Keros Therapeutics December 26, 2025
Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharma focused on drugs that modulate the transforming growth factor-beta (TGF-β) pathway, a signaling axis implicated in several hematologic and cardiovascular disorders.
The company’s lead asset, KER-050, is in Phase II/III development for cytopenias-specifically anemia and thrombocytopenia-in myelodysplastic syndromes (MDS) and myelofibrosis (MF). If approved, KER-050 would address a market estimated at $2 billion in the U.S. alone, where current treatments (e.g., luspatercept) have limited durability. As of the most recent 10-Q, Keros reported cash and cash equivalents of roughly $120 million, giving it an estimated 12-month runway at current burn rates (~$10 million per quarter).
Beyond KER-050, the pipeline includes KER-012, a Phase II candidate for pulmonary arterial hypertension (PAH) and related cardiovascular disease, and KER-065, a Phase I program targeting neuromuscular disorders. Keros also holds a collaboration with Hansoh Healthtech (Shanghai) to develop, manufacture, and commercialize elritercept-based products, providing a potential non-U.S. revenue stream and shared R&D costs.
Sector-wide, biotechnology R&D spending is projected to grow ~8 % YoY, driven by advances in protein therapeutics and regulatory incentives for orphan diseases-factors that could enhance Keros’s access to capital and partnership opportunities. However, the company remains highly dependent on the success of its lead program, and any delay or negative data in the KER-050 trials would materially impair its valuation.
For a deeper quantitative view of KROS’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 64.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 36.32 > 1.0 |
| NWC/Revenue: 281.8% < 20% (prev 80.3k%; Δ -80.1k% < -1%) |
| CFO/TA 0.12 > 3% & CFO 88.8m > Net Income 64.4m |
| Net Debt (-676.0m) to EBITDA (82.4m): -8.21 < 3 |
| Current Ratio: 29.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.6m) vs 12m ago 12.52% < -2% |
| Gross Margin: 99.42% > 18% (prev -0.76%; Δ 10.0k% > 0.5%) |
| Asset Turnover: 37.32% > 50% (prev 0.11%; Δ 37.21% > 0%) |
| Interest Coverage Ratio: 8.26 > 6 (EBITDA TTM 82.4m / Interest Expense TTM 9.80m) |
Altman Z'' -7.32
| A: 0.94 (Total Current Assets 719.3m - Total Current Liabilities 24.1m) / Total Assets 742.8m |
| B: -0.62 (Retained Earnings -458.3m / Total Assets 742.8m) |
| C: 0.12 (EBIT TTM 80.9m / Avg Total Assets 661.0m) |
| D: -11.69 (Book Value of Equity -458.3m / Total Liabilities 39.2m) |
| Altman-Z'' Score: -7.32 = D |
Beneish M 1.00
| DSRI: 0.01 (Receivables 5.57m/1.92m, Revenue 246.7m/651.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.37 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 379.0 (Revenue 246.7m / 651.0k) |
| TATA: -0.03 (NI 64.4m - CFO 88.8m) / TA 742.8m) |
| Beneish M-Score: 266.8 (Cap -4..+1) = D |
What is the price of KROS shares?
Over the past week, the price has changed by -1.97%, over one month by -0.76%, over three months by +20.89% and over the past year by +65.32%.
Is KROS a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KROS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.5 | 27.7% |
| Analysts Target Price | 23.5 | 27.7% |
| ValueRay Target Price | 20 | 8.8% |
KROS Fundamental Data Overview February 03, 2026
P/E Forward = 48.7805
P/S = 2.2116
P/B = 0.7755
Revenue TTM = 246.7m USD
EBIT TTM = 80.9m USD
EBITDA TTM = 82.4m USD
Long Term Debt = 17.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.32m USD (from shortTermDebt, last quarter)
Debt = 17.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -676.0m USD (from netDebt column, last quarter)
Enterprise Value = -130.4m USD (545.6m + Debt 17.4m - CCE 693.5m)
Interest Coverage Ratio = 8.26 (Ebit TTM 80.9m / Interest Expense TTM 9.80m)
EV/FCF = -1.50x (Enterprise Value -130.4m / FCF TTM 87.1m)
FCF Yield = -66.78% (FCF TTM 87.1m / Enterprise Value -130.4m)
FCF Margin = 35.30% (FCF TTM 87.1m / Revenue TTM 246.7m)
Net Margin = 26.12% (Net Income TTM 64.4m / Revenue TTM 246.7m)
Gross Margin = 99.42% ((Revenue TTM 246.7m - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 97.23% (prev 97.96%)
Tobins Q-Ratio = -0.18 (set to none) (Enterprise Value -130.4m / Total Assets 742.8m)
Interest Expense / Debt = 56.22% (Interest Expense 9.80m / Debt 17.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 63.9m (EBIT 80.9m * (1 - 21.00%))
Current Ratio = 29.86 (Total Current Assets 719.3m / Total Current Liabilities 24.1m)
Debt / Equity = 0.02 (Debt 17.4m / totalStockholderEquity, last quarter 703.6m)
Debt / EBITDA = -8.21 (Net Debt -676.0m / EBITDA 82.4m)
Debt / FCF = -7.76 (Net Debt -676.0m / FCF TTM 87.1m)
Total Stockholder Equity = 677.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.75% (Net Income 64.4m / Total Assets 742.8m)
RoE = 9.51% (Net Income TTM 64.4m / Total Stockholder Equity 677.7m)
RoCE = 11.64% (EBIT 80.9m / Capital Employed (Equity 677.7m + L.T.Debt 17.4m))
RoIC = 9.44% (NOPAT 63.9m / Invested Capital 677.7m)
WACC = 6.35% (E(545.6m)/V(563.1m) * Re(6.55%) + (debt cost/tax rate unavailable))
Discount Rate = 6.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 16.12%
[DCF Debug] Terminal Value 86.85% ; FCFF base≈87.1m ; Y1≈107.4m ; Y5≈182.9m
Fair Price DCF = 173.9 (EV 4.62b - Net Debt -676.0m = Equity 5.30b / Shares 30.5m; r=6.35% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 46.06 | EPS CAGR: 33.46% | SUE: 0.52 | # QB: 0
Revenue Correlation: 46.49 | Revenue CAGR: -8.62% | SUE: 0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.59 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.94 | Chg30d=-0.055 | Revisions Net=+6 | Growth EPS=-226.2% | Growth Revenue=-94.9%